The commercial success of cell therapies is continuing to grow! With a recent TIL approval, a shift to earlier line CAR-T treatment, and further approvals set for this year, 2024 will be pivotal to demonstrate the clinical benefit of cell therapies and advance breakthroughs in solid tumors and autoimmunity.

That’s why now’s the time to join the 9th CAR-TCR Summit: the industry’s definitive forum committed to progressing end-to-end cell therapy development. This year’s 2-day conference will accommodate in-depth tracks covering Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, Analytical Development and Supply Chain & Clinical Operations.

This is your team’s one-stop shop for all functions to discover cutting-edge innovations, significant clinical data and gain insights into how to conquer the bottlenecks withholding optimal durability, accessibility, safety and cost-efficiency.

Join 130+ expert speakers and 1,000+ cell therapy experts to collaborate to achieve the shared goal of delivering these curative treatments to the ever-growing population of patients in need.

View the Full Agenda to see the speaker faculty, what’s new for 2024, full session details, who you will meet and much more!

1,000+ Attendees

Spanning all functions, all stages of development and all approaches

130+ Expert Speakers

From pioneering academics, innovative biotechs and heavyweight pharma

9+ Hours of Networking

Including structured sessions, drinks receptions, private lunches, 1-1 meetings and more

7 Refined Tracks

Covering everything from discovery to clinical development to manufacturing to clinical operations

5 Bonus Days

Deep diving into autoimmune indications, solid tumors, investment, automation and fundamentals

View the Full Agenda Now:

9th CAR-TCR Summit - Full Agenda Cover

The summit is a privileged meeting to assess the status, trends, challenges and opportunities in our field, as well as to interact with peers and technology/solution providers... We’re looking forward to the 2024 edition which will shed light on the broadening of CAR-T applicability
David Sourdive, Co-Founder & Executive Vice President, CMC & Manufacturing, Cellectis Stem Cells

Cellectis (2)
CAR-TCR23-321 (1)
Partnership Opps (5)

2024 Expert Speakers:

Who Attended in 2023:

The 9th CAR-TCR Summit provides a great opportunity to stay up to date on the recent advancements in the ever-expanding Cell therapy space. Looking forward to learning, networking, and sharing insights
Arun Pores Fernando, Director, Business Development, Search & Evaluation, Cell Therapy, Bristol Myers Squibb

Bristol Myers Squibb

What's New for 2024?

& Strategy

Hear the decision-making process behind investors and big pharma search and evaluation teams and discuss methods to facilitate market access and pipeline strategy.

Carl June
CAR-TCR Travel Fund Award 

This award, presented by Dr. Carl June himself, will enable selected academics to attend for free, to engage with the field and further advance their innovative research.

Solid Tumors

Battle the immunosuppressive tumor microenvironment, optimize armoring and combination strategies and boost penetration to ultimately transform anti-tumor responses.

Automation & Manufacturing Technology Focus Day

Hear how you can integrate automated processes at various stages of production to achieve operational excellence.

New Speaking Companies:

CAR-T - new speaking companies

Lead Partner

Expertise Partners

The 9th CAR-TCR Summit provides forums for industry leaders, scientists and related experts in CAR/TCR technology and product development to interact and discuss this fast moving and highly complex field.
Justin McCue, Chief Technology Officer, TScan Therapeutics

TScan Therapeutics